NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report released on Tuesday. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NURO stock opened at $4.04 on Tuesday. The company has a fifty day moving average of $3.98 and a 200-day moving average of $3.86. NeuroMetrix has a one year low of $2.66 and a one year high of $4.73. The stock has a market capitalization of $8.25 million, a PE ratio of -0.88 and a beta of 2.20.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. The company had revenue of $0.59 million for the quarter. During the same period last year, the firm posted ($1.66) EPS.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.